Stoke Therapeutics Grants Stock Options to New Employees Under 2023 Inducement Plan
Stoke Therapeutics Inc. has granted stock options to purchase a total of 195,800 shares of common stock to ten new employees. The options have an exercise price of $35.60 per share, matching the company's closing stock price on September 15, 2025. Each option will vest over four years, with one quarter of the shares vesting on the first anniversary of the grant date and the remaining shares vesting monthly over the subsequent three years. The options have a ten-year term and are subject to the terms of the 2023 Inducement Plan and the corresponding stock option agreements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251016067722) on October 16, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。